Log In
Print this Print this

Subcutaneous Benlysta, belimumab

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionSubcutaneous formulation of a human mAb against BLyS (BAFF)
Molecular Target BLyS (BAFF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationLupus
Indication DetailsTreat active, autoantibody-positive systemic lupus erythematosus (SLE)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today